Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Cancer

Date Submitted: Jun 7, 2026
Open Peer Review Period: Jun 11, 2026 - Aug 6, 2026
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).

Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Regional Disparities, Risk Profiles, and Future Trajectories of Digestive System Cancers in East Asia: An Analysis of the Global Burden of Disease Study 2023

  • Yongshuai Wu; 
  • Ruizhi Cai; 
  • Xiangxiang Hao; 
  • Kewei Jiang; 
  • Hongpeng Jiang

ABSTRACT

Background:

East Asia is the global epicenter of digestive system cancers (DSCs), yet location-specific evidence on regional burden and differentiated risk etiologies remains limited.

Objective:

This study aimed to evaluate the burden, risk profiles, and trajectories through 2050 for six DSCs across five East Asian locations, including China mainland, North Korea, South Korea, Japan and Taiwan.

Methods:

Incidence, prevalence, mortality, and disability-adjusted life years were extracted from the Global Burden of Disease (GBD) 2023 study. Trends were quantified via average annual percent changes (AAPCs). Random Forest and Gamma regression analyzed data from 204 countries to derive relative risks (RRs). Region-specific SHAP values were subsequently extracted to rank local risk contributions. Bayesian models projected incidence to 2050.

Results:

A sub-regional divide emerged. Infection-associated esophageal cancer mortality in China mainland (AAPC -3.59) and stomach cancer mortality in South Korea (AAPC -5.15) fell. Conversely, geriatric colorectal and pancreatic cancers surged in industrialized zones, with Taiwan recording the highest colorectal incidence (ASIR 373.96). Regional SHAP rankings revealed marked etiologic heterogeneity. High trans-fatty acids (RR 1.216, 95% CI 1.102–1.346; P < 0.001) constituted the leading gallbladder cancer contributor in South Korea. Alcohol (RR 1.143, 95% CI 1.059–1.235; P < 0.001) predominantly impacted colorectal cancer across China mainland, Japan, and South Korea. Additionally, red meat (RR 1.135, 95% CI 1.029–1.253; P = 0.01) and BMI (RR 1.103, 95% CI 1.016–1.199; P = 0.03) primarily contributed to stomach cancer in China mainland. By 2050, pancreatic cancer escalates universally, whereas colorectal cancer trajectories diverge regionally.

Conclusions:

East Asia faces individualized DSC imbalances. This dual burden of persistent infection-driven reservoirs and surging geriatric metabolic malignancies highlights the potential need for location-specific screening and precision prevention.


 Citation

Please cite as:

Wu Y, Cai R, Hao X, Jiang K, Jiang H

Regional Disparities, Risk Profiles, and Future Trajectories of Digestive System Cancers in East Asia: An Analysis of the Global Burden of Disease Study 2023

JMIR Preprints. 07/06/2026:103898

DOI: 10.2196/preprints.103898

URL: https://preprints.jmir.org/preprint/103898

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.